EGIS 7229

Drug Profile

EGIS 7229

Alternative Names: S 21407

Latest Information Update: 15 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Egis Pharmaceuticals; Servier
  • Developer Egis Pharmaceuticals
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 15 Feb 2006 No development reported - Preclinical for Arrhythmias in Hungary (unspecified route)
  • 23 Sep 2002 A study has been added to the Arrythmias therapeutic trials section
  • 28 Aug 2001 A preclinical study has been added to the Arrhythmias pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top